{
    "clinical_study": {
        "@rank": "25163", 
        "arm_group": {
            "arm_group_label": "QTI571", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive QTI571 during 3 years."
        }, 
        "brief_summary": {
            "textblock": "To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are\n      benefitting from treatment with QTI571."
        }, 
        "brief_title": "Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension\n             (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in\n             Japan.\n\n          -  Patient is currently benifitting form the treatment with QTI571 in the opinion of the\n             investigator.\n\n        Exclusion Criteria:\n\n          -  Patient has been permanently discontinued from QTI571 study treatment in the parent\n             study.\n\n          -  Concomitant use of oral vitamin K antagonist medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042014", 
            "org_study_id": "CQTI571AJP01"
        }, 
        "intervention": {
            "arm_group_label": "QTI571", 
            "description": "QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.", 
            "intervention_name": "QTI571", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pulmonary arterial hypertension, QTI571, open label study", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sendai-city", 
                        "country": "Japan", 
                        "state": "Miyagi", 
                        "zip": "980-8574"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8655"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mitaka-city", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "181-8611"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All Serious Adverse events will be evaluated and reported for all participants receiving QTI571.", 
            "measure": "Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}